Novocure up after quarterly sales beat estimates

NovoCure

24/07/2025 14:06

** Shares of cancer therapy maker Novocure NVCR.O up 2% at $16.84 premarket

** Company posts Q2 revenue of $158.8 million, compared with analysts' average expectations of $154.2 million - data compiled by LSEG

** J.P.Morgan says Q2 revenue "driven primarily by active patient growth across major markets"

** Novocure plans to submit a premarket approval application to the FDA for pancreatic cancer treatment in Q3 2025

** "We believe it may take getting closer to meaningful rev growth from these new opportunities for the stock to work," JPM adds

** Up to last close, stock down 44.6% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))